Frequency of HIV diagnoses among people using oral and LA PrEP

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness
• If ‘other’, further details on the scope of the study:
  Effectiveness Evaluation

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine:
  APRETUDE
• Study drug International non-proprietary name (INN) or common name:
  CABOTEGRAVIR
• Anatomical Therapeutic Chemical (ATC) code:
  (J05AJ04) cabotegravir

  cabotegravir

Population studied

• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  23000

Study design details

• Main study objective:
  To assess the annual incidence of HIV diagnoses among all people without HIV in current study.
• Outcomes:
  - Annual number of new HIV diagnoses; - PrEP use, characteristics among people with an incident HIV diagnosis; - Characteristics of people who initiate oral and LA PrEP; - Incidence of HIV diagnoses following oral/LA PrEP initiation; - Days with an oral PrEP prescription and LA PrEP coverage; - Frequency of HIV testing and STI screening at oral/LA PrEP initiation; - Characteristics among people who could benefit from PrEP
• Data analysis plan:
  The analysis will be performed on OPERA cohort using secondary data from electronic medical records.